Head to head
BPC-157 vs TB-500
Two compounds, one grading system.
Same evidence tier — but TB-500 carries more randomised trials (2 vs 0).
01
At a glance
BPC-157Emerging
Extensive animal healing data. Essentially no controlled human trials.
298publications
0RCTs
TB-500Emerging
Synthetic fragment of thymosin beta-4. Animal repair data; human data scarce.
110publications
2RCTs
02
Side by side
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Goal | Healing & repair | Healing & repair |
| Evidence | Emerging | Emerging |
| Publications | 298 | 110 |
| Randomised trials | 0 | 2 |
| Sport (WADA) | S0 — prohibited | S2 — prohibited |
| US compounding | PCAC-voted for 503A review | PCAC-voted for 503A review |
03
Claims vs data
BPC-157 — claims vs data
| Accelerates tendon and ligament healing | animal data only |
| Heals the gut lining | animal data only |
| Reverses existing injury in humans | overreach |
| Well tolerated in reported use | partially true |
TB-500 — claims vs data
| Improves soft-tissue recovery | animal data only |
| Banned in competitive sport | supported |